Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial

• Published in: Gut Vol. 29; no. 3; pp. 279 - 283
• Main Authors: Humphreys, H, Bourke, S, Dooley, C, McKenna, D, Power, B, Keane, C T, Sweeney, E C, O'Moráin, C
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01-03-1988; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Biological and medical sciences; Campylobacter Infections - complications; Campylobacter Infections - drug therapy; Cimetidine - therapeutic use; Digestive system; Drug Therapy, Combination; Esophagitis - drug therapy; Esophagitis - etiology; Female; Gastritis - drug therapy; Gastritis - etiology; Humans; Male; Medical sciences; Organometallic Compounds - therapeutic use; Peptic Ulcer - drug therapy; Peptic Ulcer - etiology; Pharmacology. Drug treatments; Prospective Studies; Random Allocation; Human; Antiulcer agent; Antihistaminic; Colloid; Infection; Campylobacter infection; Chemotherapy; Gastroduodenal; Treatment; Bacteriosis; Bismuth; Digestive diseases; Ulcer; Comparative study
• ISSN: 0017-5749; 1468-3288; 1458-3288
• DOI: 10.1136/gut.29.3.279

This study investigated the effect of colloidal bismuth subcitrate and cimetidine on Campylobacter pylori in peptic disease. In 74% of 135 patients with peptic disease diagnosed at endoscopy C pylori was detected before treatment. Compared with cimetidine, colloidal bismuth subcitrate significantly decreased the incidence of C pylori after six weeks of treatment (p less than 0.001). In the colloidal bismuth subcitrate group, subsequent healing of the lesion was correlated with the clearance of C pylori, unlike in the cimetidine group. C pylori was strongly associated with the presence of histological gastritis, which was decreased by colloidal bismuth subcitrate (p less than 0.001).